235 related articles for article (PubMed ID: 26446600)
1. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.
Asokan M; Rudicell RS; Louder M; McKee K; O'Dell S; Stewart-Jones G; Wang K; Xu L; Chen X; Choe M; Chuang G; Georgiev IS; Joyce MG; Kirys T; Ko S; Pegu A; Shi W; Todd JP; Yang Z; Bailer RT; Rao S; Kwong PD; Nabel GJ; Mascola JR
J Virol; 2015 Dec; 89(24):12501-12. PubMed ID: 26446600
[TBL] [Abstract][Full Text] [Related]
2. Engineering multi-specific antibodies against HIV-1.
Padte NN; Yu J; Huang Y; Ho DD
Retrovirology; 2018 Aug; 15(1):60. PubMed ID: 30157871
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype.
Mabuka J; Goo L; Omenda MM; Nduati R; Overbaugh J
AIDS; 2013 Jun; 27(10):1535-44. PubMed ID: 23856624
[TBL] [Abstract][Full Text] [Related]
4. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
Mkhize NN; Yssel AEJ; Kaldine H; van Dorsten RT; Woodward Davis AS; Beaume N; Matten D; Lambson B; Modise T; Kgagudi P; York T; Westfall DH; Giorgi EE; Korber B; Anthony C; Mapengo RE; Bekker V; Domin E; Eaton A; Deng W; DeCamp A; Huang Y; Gilbert PB; Gwashu-Nyangiwe A; Thebus R; Ndabambi N; Mielke D; Mgodi N; Karuna S; Edupuganti S; Seaman MS; Corey L; Cohen MS; Hural J; McElrath MJ; Mullins JI; Montefiori D; Moore PL; Williamson C; Morris L
PLoS Pathog; 2023 Jun; 19(6):e1011469. PubMed ID: 37384759
[TBL] [Abstract][Full Text] [Related]
5. Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4.
Welles HC; King HAD; Nettey L; Cavett N; Gorman J; Zhou T; Tsybovsky Y; Du R; Song K; Nguyen R; Ambrozak D; Ransier A; Schramm CA; Doria-Rose NA; Swanstrom AE; Hoxie JA; LaBranche C; Montefiori DC; Douek DC; Kwong PD; Mascola JR; Roederer M; Mason RD
PLoS Pathog; 2022 Jun; 18(6):e1010574. PubMed ID: 35709309
[TBL] [Abstract][Full Text] [Related]
6. Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth.
van Dorsten RT; Wagh K; Moore PL; Morris L
Front Immunol; 2021; 12():734110. PubMed ID: 34603312
[TBL] [Abstract][Full Text] [Related]
7. Engineering antibody-based molecules for HIV treatment and cure.
Tuyishime M; Ferrari G
Curr Opin HIV AIDS; 2020 Sep; 15(5):290-299. PubMed ID: 32732551
[TBL] [Abstract][Full Text] [Related]
8. Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design.
Holt GT; Gorman J; Wang S; Lowegard AU; Zhang B; Liu T; Lin BC; Louder MK; Frenkel MS; McKee K; O'Dell S; Rawi R; Shen CH; Doria-Rose NA; Kwong PD; Donald BR
Cell Rep; 2023 Jul; 42(7):112711. PubMed ID: 37436900
[TBL] [Abstract][Full Text] [Related]
9. Ultrapotent Broadly Neutralizing Human-llama Bispecific Antibodies against HIV-1.
Xu J; Zhou T; McKee K; Zhang B; Liu C; Nazzari AF; Pegu A; Shen CH; Becker JE; Bender MF; Chan P; Changela A; Chaudhary R; Chen X; Einav T; Kwon YD; Lin BC; Louder MK; Merriam JS; Morano NC; O'Dell S; Olia AS; Rawi R; Roark RS; Stephens T; Teng IT; Tourtellott-Fogt E; Wang S; Yang ES; Shapiro L; Tsybovsky Y; Doria-Rose NA; Casellas R; Kwong PD
Adv Sci (Weinh); 2024 May; ():e2309268. PubMed ID: 38704686
[TBL] [Abstract][Full Text] [Related]
10. Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies.
Gardner MR; Fetzer I; Kattenhorn LM; Davis-Gardner ME; Zhou AS; Alfant B; Weber JA; Kondur HR; Martinez-Navio JM; Fuchs SP; Desrosiers RC; Gao G; Lifson JD; Farzan M
Mol Ther; 2019 Mar; 27(3):650-660. PubMed ID: 30704961
[TBL] [Abstract][Full Text] [Related]
11. Characterization of human IgG repertoires in an acute HIV-1 infection.
Chen W; Prabakaran P; Zhu Z; Feng Y; Streaker ED; Dimitrov DS
Exp Mol Pathol; 2012 Dec; 93(3):399-407. PubMed ID: 23036472
[TBL] [Abstract][Full Text] [Related]
12. Antibody class-switching as a strategy to improve HIV-1 neutralization.
Scheepers C; Richardson SI; Moyo-Gwete T; Moore PL
Trends Mol Med; 2022 Nov; 28(11):979-988. PubMed ID: 36117072
[TBL] [Abstract][Full Text] [Related]
13. Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies.
Chu TH; Crowley AR; Backes I; Chang C; Tay M; Broge T; Tuyishime M; Ferrari G; Seaman MS; Richardson SI; Tomaras GD; Alter G; Leib D; Ackerman ME
PLoS Pathog; 2020 Feb; 16(2):e1008083. PubMed ID: 32092122
[TBL] [Abstract][Full Text] [Related]
14. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.
Mayer BT; deCamp AC; Huang Y; Schiffer JT; Gottardo R; Gilbert PB; Reeves DB
PLoS Comput Biol; 2022 Apr; 18(4):e1010003. PubMed ID: 35385469
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Casazza JP; Cale EM; Narpala S; Yamshchikov GV; Coates EE; Hendel CS; Novik L; Holman LA; Widge AT; Apte P; Gordon I; Gaudinski MR; Conan-Cibotti M; Lin BC; Nason MC; Trofymenko O; Telscher S; Plummer SH; Wycuff D; Adams WC; Pandey JP; McDermott A; Roederer M; Sukienik AN; O'Dell S; Gall JG; Flach B; Terry TL; Choe M; Shi W; Chen X; Kaltovich F; Saunders KO; Stein JA; Doria-Rose NA; Schwartz RM; Balazs AB; Baltimore D; Nabel GJ; Koup RA; Graham BS; Ledgerwood JE; Mascola JR;
Nat Med; 2022 May; 28(5):1022-1030. PubMed ID: 35411076
[TBL] [Abstract][Full Text] [Related]
16. Predicting neutralization susceptibility to combination HIV-1 monoclonal broadly neutralizing antibody regimens.
Williamson BD; Wu L; Huang Y; Hudson A; Gilbert PB
bioRxiv; 2023 Dec; ():. PubMed ID: 38168308
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies: Potential immunotherapies for HIV treatment.
Fabozzi G; Pegu A; Koup RA; Petrovas C
Methods; 2019 Feb; 154():118-124. PubMed ID: 30352254
[TBL] [Abstract][Full Text] [Related]
18. Circulating immunoglobulins and transient lymphocytopenia in a sub-study of CAPRISA 012B, testing HIV monoclonal antibodies in a phase 1 trial.
Sobia P; Mahomed S; Sivro A; Paul S; Osman F; Harkoo I; Garrett N; Karim QA; Karim SSA; Archary D
Sci Rep; 2024 Jun; 14(1):13499. PubMed ID: 38866888
[TBL] [Abstract][Full Text] [Related]
19. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses.
Radić L; Sliepen K; Yin V; Brinkkemper M; Capella-Pujol J; Schriek AI; Torres JL; Bangaru S; Burger JA; Poniman M; Bontjer I; Bouhuijs JH; Gideonse D; Eggink D; Ward AB; Heck AJR; Van Gils MJ; Sanders RW; Schinkel J
iScience; 2023 Apr; 26(4):106540. PubMed ID: 37063468
[TBL] [Abstract][Full Text] [Related]
20. Frequency-potency analysis of IgG+ memory B cells delineates neutralizing antibody responses at single-cell resolution.
Tenggara MK; Oh SH; Yang C; Nariya HK; Metz AM; Upadhyay AA; Gudipati DR; Guo L; McGhee EG; Gill K; Viox EG; Mason RD; Doria-Rose NA; Foulds KE; Mascola JR; Du Y; Fu H; Altman JD; Yan Q; Sheng Z; Bosinger SE; Kong R
Cell Rep; 2024 Mar; 43(3):113948. PubMed ID: 38483908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
